SmithKline IBS Research Is One Of Nine Divestments Under FTC Order

SmithKline Beecham is required to divest its rights to Alizyme's irritable bowel syndrome therapy renzapride under the FTC consent order allowing the GlaxoSmithKline merger despite Glaxo's recent withdrawal of Lotronex.